Bedlington, NicoleAbifadel, MarianneBeger, BirgitBourbon, MafaldaBueno, HéctorCeska, RichardCillíková, KristýnaCimická, ZdenkaDaccord, MagdalenaBeaufort, Carine deDharmayat, Kanika I.Ference, Brian A.Freiberger, TomášGeanta, MariusGidding, Samuel S.Grošelj, UrhHalle, MartinJohnson, NeilNovakovic, TanjaMájek, OndrejPallidis, AthanasiosPeretti, NoelPinto, Fausto J.Ray, Kausik KoshRees, BleddynReeve, JohnReiner, ŽeljkoSantos, Raul D.Schunkert, HeribertŠikonja, JakaSokolovic, MilkaTokgözoglu, LaleVrablík, MichalWiegman, AlbertGutiérrez-Ibarluzea, Iñaki2023-01-302023-01-302022-09-30GMS Health Innov Technol. 2022 Sep 30;16:Doc04. doi: 10.3205/hta000136. eCollection 2022. Review2698-6388http://hdl.handle.net/10400.18/8466ReviewFamilial Hypercholesterolaemia (FH) is severely under-recognized, under-diagnosed and under-treated in Europe, leading to a significantly higher risk of premature cardiovascular diseases in those affected. FH stands for inherited, very high cholesterol and affects 1:300 individuals regardless of their age, race, sex, and lifestyle, making it the most common inherited metabolic disorder and a non-modifiable cardiovascular disease risk factor in the world..engFamilial HypercholesterolaemiaFHScreeningChildrenCardiovascular DiseaseCVDPreventionCardiovascular HealthCVHDeclarationPublic HealthHealth SystemsEUEuropeEU Best PracticeImplementationDoenças Cardio e Cérebro-vascularesjournal article10.3205/hta000136